Table 3.
Mean cost per patient of controlled severe asthma (CSA) and uncontrolled severe asthma (UCSA).
| Cost (USD) |
|||||||
|---|---|---|---|---|---|---|---|
| Total, n = 60 | CSA, n = 37 | UCSA, n = 23 | |||||
| 2018 | Median (Q1-Q3) | Minimum-Maximum | Median (Q1-Q3) | Minimum-Maximum | Median (Q1-Q3) | Minimum-Maximum | P |
| Laboratories | 11.2 (0–25.3) | 0–54.2 | 11.23 (0–32.71) | 0–54.2 | 11.2 (0.0–25.3) | 0.0–40.2 | 0.092 |
| Medications | 6629.2 (6476.8–6778.1) | 3630.2–9058.8 | 6607.7 (6456.4–6712.6) | 6205.3–7211.6 | 6731.0 (6573.0–6922.0) | 3630.0–9059.0 | |
| Consultations | 1351.5 (1351.5–1351.5) | 1351.5–1351.5 | 1351.5 (1351.5–1351.5) | 1351.5–1351.5 | 1351.5 (1351.5–1351.5) | 1351.5–1351.5 | 0.053 |
| Total |
8002.1 (7843.5–8150.5) |
5006.9–10450.4 |
7967.3 (7814–8094.1) |
7572.4–8603.2 |
8094.0 (7924.0–8287.0) |
5007.0–10450.0 |
0.065 |
| 2019 |
CSA, n = 38 |
UCSA, n = 22 |
|||||
| Laboratories | 0.0 (0.0–26.2) | 0.0–56.1 | 0.0 (0.0–26.2) | 0–56.1 | 0.0 (0.0–30.0) | 0.0–56.1 | 0.93 |
| Medications | 6905.0 (6766.0–7013.0) | 6417.0–10593.0 | 6823.6 (6621.5–6891.9) | 6417.3–6954.3 | 7075.0 (7001.0–7376.0) | 6908.0–10593.0 | 0.001 |
| Consultations | 1399.1 (1399.1–1399.1) | 1399.1–1399.1 | 1399.1 (1399.1–1399.1) | 1399.1–1399.1 | 1399.1 (1399.1–1399.1) | 1399.1–1399.1 | |
| Total | 8321.0 (8193.0–8435.0) | 7816.0–11992.0 | 8239.2 (8039.3–8317.4) | 7816.4–8358.2 | 8482.0 (8426.0–8775.0) | 8359.0–11992.0 | 0.001 |
UCSA was defined by the presence of at least one exacerbation in the year; P, p-value resulting from the Mann-Whitney test; Q1 and Q3, quartiles 1 and 3 respectively